Ascendis Pharma A/S (NASDAQ:ASND) Sees Unusually-High Trading Volume

Shares of Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) saw an uptick in trading volume on Thursday . 616,993 shares were traded during mid-day trading, an increase of 53% from the previous session's volume of 402,361 shares.The stock last traded at $113.95 and had previously closed at $112.93.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on ASND. Stifel Nicolaus assumed coverage on shares of Ascendis Pharma A/S in a research report on Friday, May 31st. They set a "buy" rating and a $200.00 price target on the stock. Citigroup decreased their target price on Ascendis Pharma A/S from $193.00 to $178.00 and set a "buy" rating for the company in a research report on Wednesday, September 4th. Morgan Stanley upped their price target on Ascendis Pharma A/S from $116.00 to $140.00 and gave the company an "equal weight" rating in a research report on Thursday, May 16th. JPMorgan Chase & Co. decreased their price objective on shares of Ascendis Pharma A/S from $174.00 to $165.00 and set an "overweight" rating for the company in a report on Wednesday, September 4th. Finally, Cantor Fitzgerald lowered their target price on shares of Ascendis Pharma A/S from $173.00 to $170.00 and set an "overweight" rating for the company in a research note on Wednesday, September 4th. Two analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $187.08.

Ascendis Pharma A/S Stock Performance

The stock has a market capitalization of $6.63 billion, a price-to-earnings ratio of -11.84 and a beta of 0.63. The business's 50 day simple moving average is $132.78 and its 200-day simple moving average is $137.00.

Hedge Funds Weigh In On Ascendis Pharma A/S

Hedge funds and other institutional investors have recently made changes to their positions in the business. Private Ocean LLC bought a new stake in Ascendis Pharma A/S during the 1st quarter valued at $36,000. GAMMA Investing LLC grew its stake in shares of Ascendis Pharma A/S by 52.0% in the first quarter. GAMMA Investing LLC now owns 298 shares of the biotechnology company's stock worth $45,000 after purchasing an additional 102 shares in the last quarter. Quadrant Capital Group LLC grew its stake in shares of Ascendis Pharma A/S by 90.4% in the fourth quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company's stock worth $40,000 after purchasing an additional 151 shares in the last quarter. EverSource Wealth Advisors LLC grew its stake in shares of Ascendis Pharma A/S by 37.6% in the fourth quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company's stock worth $42,000 after purchasing an additional 91 shares in the last quarter. Finally, Bessemer Group Inc. grew its stake in shares of Ascendis Pharma A/S by 61.0% in the first quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company's stock worth $132,000 after purchasing an additional 332 shares in the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.